Methods and compositions for the sustained release of chromium

• US 9,119,835 B2
• Filed: 11/18/2011
• Issued: 09/01/2015
• Est. Priority Date: 03/13/2007
• Status: Expired due to Fees

• Current Assignee: Nutrition21 LLC
• Original Assignee: JDS Therapeutics LLC
• Inventors: Komorowski, James R.
• Primary Examiner(s): STANFIELD, CHERIE MICHELLE
• Application Number:
  US13/300,059
• Publication Number:
  US 20120128794A1
• Time in Patent Office: 1,383 Days
• US Class Current: 1/1
• CPC Class Codes: A23L 33/165 Complexes or chelates
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2250/1586 Chromium
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 31/4172 Imidazole-alkanecarboxylic acids, e.g. histidine
• CPC Class Codes: A61K 31/4402 only substituted in position 2, e.g. pheniramine, bisacodyl
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 47/545 Heterocyclic compounds A61K47/558 takes precedence
• CPC Class Codes: A61K 47/547 Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.

Claims

1. A method for reducing the risk of developing cardiometabolic syndrome in a subject, comprising:

co-administering to said subject a therapeutically effective amount of a synergistic ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex;

wherein the ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex is between about 1;

10 and about 10;

1.

2. The method of claim 1, wherein said hydrophilic chromium complex is selected from the group consisting of chromium histidinate, chromium acetate, chromium chloride, and chromium nicotinate.

3. The method of claim 1, wherein said hydrophilic chromium complex and said lipophilic chromium complex are administered at substantially the same time.

4. The method of claim 1, wherein said hydrophilic chromium complex and said lipophilic chromium complex are administered sequentially in either order.

5. The method of claim 1, wherein said hydrophilic chromium complex is chromium histidinate.

6. The method of claim 1, wherein said hydrophilic chromium complex is chromium acetate.

7. The method of claim 1, wherein said hydrophilic chromium complex is chromium chloride.

8. The method of claim 1, wherein said hydrophilic chromium complex is chromium nicotinate.

9. The method of claim 1, wherein said lipophilic chromium complex is chromium picolinate.

10. The method of claim 1, wherein the ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex is between about 1:

8 and about 8;

1.

11. The method of claim 1, wherein the ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex is between about 1:

4 and about 4;

1.

12. The method of claim 1, wherein the ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex is between about 1:

2 and about 2;

1.

13. The method of claim 1, wherein the subject is a mammal.

14. The method of claim 13, wherein the mammal is a human.

15. The method of claim 1, wherein the chromium is administered concurrently with a therapeutically effective amount of a cardiovascular compound.

16. The method of claim 15, wherein the cardiovascular compound is selected from the group consisting of an angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, a calcium channel blocker, an anti-thrombotic agent, a β

-adrenergic receptor antagonist, a vasodilator, a diuretic, an α

-adrenergic receptor antagonist, an antioxidant, and combinations thereof.

17. A method for treating cardiometabolic syndrome in a subject in need thereof, comprising:

identifying a subject having at least one risk factor for cardiometabolic syndrome; and

administering to said subject a therapeutically effective amount of a synergistic ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex;

wherein the ratio of chromium provided in the form of a hydrophilic chromium complex to chromium provided in the form of a lipophilic chromium complex is between about 1;

10 and about 10;

1.

18. The method of claim 17, wherein said hydrophilic chromium complex is selected from the group consisting of chromium histidinate, chromium acetate, chromium chloride, and chromium nicotinate.

19. The method of claim 17, wherein said lipophilic chromium complex is chromium picolinate.